WO2021076176A3 - Liquid emulsion therapy for treating acute cannabinoid intoxication - Google Patents

Liquid emulsion therapy for treating acute cannabinoid intoxication Download PDF

Info

Publication number
WO2021076176A3
WO2021076176A3 PCT/US2020/018830 US2020018830W WO2021076176A3 WO 2021076176 A3 WO2021076176 A3 WO 2021076176A3 US 2020018830 W US2020018830 W US 2020018830W WO 2021076176 A3 WO2021076176 A3 WO 2021076176A3
Authority
WO
WIPO (PCT)
Prior art keywords
intoxication
treating acute
liquid emulsion
emulsion composition
lipid emulsion
Prior art date
Application number
PCT/US2020/018830
Other languages
French (fr)
Other versions
WO2021076176A2 (en
Inventor
Jack Donaldson
Original Assignee
Jack Donaldson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jack Donaldson filed Critical Jack Donaldson
Priority to PCT/US2020/018830 priority Critical patent/WO2021076176A2/en
Priority claimed from US16/795,019 external-priority patent/US11504326B2/en
Publication of WO2021076176A2 publication Critical patent/WO2021076176A2/en
Publication of WO2021076176A3 publication Critical patent/WO2021076176A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A lipid emulsion composition including soybean oil, egg lecithin, glycerol and, or osmolality and method for treating acute cannabinoid intoxication or intoxication from other substances, such as alcohol or other drugs, by orally or intravenously administering this composition according to a predetermine protocol to treat patients experiencing acute cannabinoid intoxication or intoxication from other substances. The lipid emulsion composition could be administered to the intoxicated patient orally or intravenously. In some embodiments, the lipid emulsion composition includes soybean oil, egg yolk phospholipids, and glycerin.
PCT/US2020/018830 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication WO2021076176A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2020/018830 WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962807345P 2019-02-19 2019-02-19
US62/807,345 2019-02-19
US16/795,019 2020-02-18
USPCT/US2020/018830 2020-02-18
US16/795,019 US11504326B2 (en) 2019-02-19 2020-02-19 Lipid emulsion therapy for treating acute cannabinoid intoxication
PCT/US2020/018830 WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication

Publications (2)

Publication Number Publication Date
WO2021076176A2 WO2021076176A2 (en) 2021-04-22
WO2021076176A3 true WO2021076176A3 (en) 2021-07-08

Family

ID=75538889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/018830 WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication

Country Status (1)

Country Link
WO (1) WO2021076176A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081626A1 (en) * 2005-06-14 2009-03-26 William Milgram System and method for assessing cognitive function and measuring treatment efficacy
US20150253344A1 (en) * 2014-03-05 2015-09-10 John Scott Perez Method and apparatus for real-time detection of human cannabinoid intoxication
US20180344666A1 (en) * 2015-11-13 2018-12-06 Resq Pharma Inc. Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081626A1 (en) * 2005-06-14 2009-03-26 William Milgram System and method for assessing cognitive function and measuring treatment efficacy
US20150253344A1 (en) * 2014-03-05 2015-09-10 John Scott Perez Method and apparatus for real-time detection of human cannabinoid intoxication
US20180344666A1 (en) * 2015-11-13 2018-12-06 Resq Pharma Inc. Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKSEL ET AL.: "Intravenous lipid emulsion therapy for acute synthetic cannabinoid intoxication: Clinical experience in four cases", CASE REPORTS IN EMERGENCY MEDICINE, vol. 2015, 2015, pages 1 - 5, XP055838504, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/criem/2015/180921.pdf> [retrieved on 20210506] *
INTRALIPID: "Lipid emulsions for intravenous nutrition", PRODUCT MONOGRAPH, 11 May 2017 (2017-05-11), pages 1 - 36, Retrieved from the Internet <URL:https://www.fresenius-kabi.com/en-ca/documents/lntralipid-PM-ENG.pdf> [retrieved on 20210506] *

Also Published As

Publication number Publication date
WO2021076176A2 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
Mohamed et al. Current trends in pharmaceutical treatment of dry eye disease: A review
Steven et al. Semifluorinated alkane eye drops for treatment of dry eye disease—a prospective, multicenter noninterventional study
US9084801B2 (en) Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
RU2651046C2 (en) Dry eye treatment compositions
CA2838312C (en) Therapeutic application of parenteral krill oil
KR20170086111A (en) Stabilized omega-3 ophthalmic compositions
US20130245119A1 (en) Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
JPS61249918A (en) Eye drops
Hesselink et al. Resolvins and aliamides: lipid autacoids in ophthalmology–what promise do they hold?
KR20140107383A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2158915B1 (en) Acylglycerophospholipides for treating symptoms accompanying cancer
US20180344666A1 (en) Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity
WO2021076176A3 (en) Liquid emulsion therapy for treating acute cannabinoid intoxication
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
US10052352B2 (en) Therapeutic application of parenteral krill oil
Sgrignoli et al. Comparison of topical 0.03% tacrolimus in almond and linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits
Martínez et al. Tamoxifen retinal toxicity. Monitoring by multimodal imaging study
JP2008508257A (en) Compositions and methods for smoking cessation
RU2817530C1 (en) Obtaining and using hemp nanoformulation
JP5759804B2 (en) Container preparation
US20230132438A1 (en) Preparation and use of cannabis nano-formulation
CN104771354B (en) For the ophthalmically acceptable pharmaceutical preparation based on non-polar and polar lipid
Nowak et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia
Salman Ectropion, papulopustular rash and palmoplantar fissures: case report
KR20030007686A (en) Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20875972

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20875972

Country of ref document: EP

Kind code of ref document: A2